Free Trial
OTCMKTS:CPHRF

Cipher Pharmaceuticals (CPHRF) Stock Price, News & Analysis

Cipher Pharmaceuticals logo
$8.98 +0.02 (+0.24%)
As of 05/30/2025 10:58 AM Eastern

About Cipher Pharmaceuticals Stock (OTCMKTS:CPHRF)

Key Stats

Today's Range
$8.98
$8.98
50-Day Range
$7.72
$10.64
52-Week Range
$5.75
$14.60
Volume
4,560 shs
Average Volume
15,680 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

Receive CPHRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPHRF Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More Headlines

CPHRF Stock Analysis - Frequently Asked Questions

Cipher Pharmaceuticals' stock was trading at $9.9660 at the beginning of 2025. Since then, CPHRF stock has decreased by 9.9% and is now trading at $8.98.
View the best growth stocks for 2025 here
.

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) released its quarterly earnings data on Thursday, May, 5th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The firm earned $9.10 million during the quarter, compared to analyst estimates of $10.87 million.

Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/05/2016
Today
5/30/2025
Next Earnings (Estimated)
8/06/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CPHRF
Previous Symbol
NASDAQ:CPHR
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:CPHRF) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners